GB9026229D0 - Tolerogenic conjugates for suppressing immune responses - Google Patents

Tolerogenic conjugates for suppressing immune responses

Info

Publication number
GB9026229D0
GB9026229D0 GB909026229A GB9026229A GB9026229D0 GB 9026229 D0 GB9026229 D0 GB 9026229D0 GB 909026229 A GB909026229 A GB 909026229A GB 9026229 A GB9026229 A GB 9026229A GB 9026229 D0 GB9026229 D0 GB 9026229D0
Authority
GB
United Kingdom
Prior art keywords
immune responses
suppressing immune
tolerogenic
conjugates
tolerogenic conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB909026229A
Other versions
GB2238959A (en
GB2238959B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898927373A external-priority patent/GB8927373D0/en
Application filed by Individual filed Critical Individual
Publication of GB9026229D0 publication Critical patent/GB9026229D0/en
Publication of GB2238959A publication Critical patent/GB2238959A/en
Application granted granted Critical
Publication of GB2238959B publication Critical patent/GB2238959B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB9026229A 1989-12-01 1990-12-03 Antigen and conjugates thereof for suppressing immune response Expired - Fee Related GB2238959B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44426389A 1989-12-01 1989-12-01
GB898927373A GB8927373D0 (en) 1989-12-04 1989-12-04 Tolerogenic conjugates for suppressing immune responses

Publications (3)

Publication Number Publication Date
GB9026229D0 true GB9026229D0 (en) 1991-01-16
GB2238959A GB2238959A (en) 1991-06-19
GB2238959B GB2238959B (en) 1993-10-20

Family

ID=26296306

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9026229A Expired - Fee Related GB2238959B (en) 1989-12-01 1990-12-03 Antigen and conjugates thereof for suppressing immune response

Country Status (1)

Country Link
GB (1) GB2238959B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) * 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
AU8001694A (en) * 1993-11-03 1995-05-23 University Of Manitoba Cell control and suppression

Also Published As

Publication number Publication date
GB2238959A (en) 1991-06-19
GB2238959B (en) 1993-10-20

Similar Documents

Publication Publication Date Title
EP0382796A4 (en) Method for the preparation of antibody-fragment conjugates
GB8903313D0 (en) Conjugates
ZA879473B (en) Immunoglubolin conjugates
DE69026272D1 (en) Rheometer
IL92230A0 (en) Antibody-drug conjugates
GB8908250D0 (en) Formulations
GB8921470D0 (en) Vaccines
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
EP0504136A4 (en) Tolerogenic immunoglobulin-protein conjugates
HU905458D0 (en) Inflammable preparation
GB2203154B (en) Immunoglobulin conjugates
GB8919661D0 (en) Superoxide dismutase-catalase conjugates
AP9000174A0 (en) Antiparasitical formulations
GB9026229D0 (en) Tolerogenic conjugates for suppressing immune responses
ZA89524B (en) Antibody conjugates
GB8927373D0 (en) Tolerogenic conjugates for suppressing immune responses
GB8912496D0 (en) Vaccines
IL92583A0 (en) Tolerogenic immunoglobulin-protein conjugates
AU5090290A (en) Tolerogenic immunoglobulin-protein conjugates
NZ238953A (en) Antibody-superantigen conjugates
IE893616L (en) Antibody-drug conjugates
EP0453452A4 (en) Vaccine
ZA907863B (en) Vaccine conjugate
IE883489L (en) Drug-monoclonalantibody conjugates
GB9017729D0 (en) Conjugates

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19961203